The Discovery & Development Roadmap from Hit ID to IND

Driving From Hit ID to IND with Reduced Time to Clinic

Scientists looking through a microscope.

The industry average development timeline from hit ID to candidate nomination is 33-36 months, but did you know you can shave as much as a year off your program? During this seminar you’ll learn how an integrated approach to your discovery and development can save you substantial time and money on the road to IND.

Accelerate your Program

Learn how and when to plan your preclinical IND-enabling program, and discover the value of combining your target discovery, hit ID, hit-to-lead, lead optimization, safety and toxicology strategies in a holistic program that accelerates time to result.

Time to clinic can be reduced by one year with an integrated drug discovery approach, whereby target discovery, hit id, hit-to-lead, lead optimization, safety, and toxicology is managed by the same project team. The industry standard from hit id to candidate nomination is on average 33-36 months.

Charles River’s truly integrated drug discovery (IDD) services have reduced this timeline to as little as 24 months through industry-experienced, multidisciplinary teams focused on resource efficiency, scientific excellence and strategic partnerships with clients through all aspects of drug discovery. Understanding how and when to plan a preclinical investigational new drug (IND)-enabling program is an integral part of meeting specific milestones necessary for timely and efficient IND submission.

 

Presentations

A Chemistry Perspective on Integrated Drug Discovery
George Hynd, PhD, Research Leader, Medicinal Chemistry

A Biology Perspective on Integrated Drug Discovery
Sarah Almond, MSc, Associate Director, Integrated Biology

Transitioning from Drug Discovery to IND
Sam Chuang, PhD, Director, Scientific Advisory Services

A Chemistry Perspective on Integrated Drug Discovery
George Hynd, PhD, Research Leader, Medicinal Chemistry

 

A Biology Perspective on Integrated Drug Discovery
Sarah Almond, MSc, Associate Director, Integrated Biology

 

Transitioning from Drug Discovery to IND
Sam Chuang, PhD, Director, Scientific Advisory Services

George Hynd headshot

George Hynd, PhD
Research Leader, Medicinal Chemistry

George Hynd received his PhD in chemistry from the University of Dundee. He continued his training as a post-doctoral research fellow at Clemson University, South Carolina, and at Northeastern University in Boston, Massachusetts. He then moved to the University of Bristol where he held the position of Research Officer overseeing a team of post-graduate researchers and post-doctoral fellows. George is currently a Research Leader at Charles River Discovery in Harlow where he is responsible for leading integrated drug discovery programs. He has extensive medicinal chemistry experience (>18 years) and a significant track record in leading programs that have delivered clinical candidates. He is also a co-author and co-inventor on over 80 scientific publications.


Sarah Almond headshot

Sarah Almond, MSc
Associate Director, Integrated Biology

Sarah has over 20 years’ experience in pharmaceutical research gained from companies such as GE, Merck Sharp Dohme, AstraZeneca, Takeda and Mundipharma Research Ltd. An in vivo pharmacologist by training, her experience is broad and covers drug discovery, drug safety and translational medicine from target identification through to non-clinical support for PII clinical trials. An experienced drug discovery project leader, Sarah has led projects to candidate selection in the neuroscience and inflammation areas. At Charles River, she is responsible for assay development and in vitro pharmacology across a range of IDD projects.


Samuel Chuang headshot

Sam Chuang, PhD
Director, Scientific Advisory Services

An experienced scientist, Sam Chuang collaborates with pharmaceutical and biotechnology companies worldwide, advising on drug development programs and study designs and monitoring nonclinical regulatory packages. He provides scientific and regulatory expertise covering a variety of drug classes (small to large molecule), therapeutic areas, routes of administration, and animal species. He manages multidisciplinary research teams for multiple drug development programs from target identification and drug discovery to preclinical safety programs. Sam is a member of the Society of Toxicology.